Intravesical gemcitabine in superficial bladder tumours preliminary results of a phase I-II study

INTRODUCTION & OBJECTIVES: Gemcttabme is a pro-drug requmng intracellular phosphorylation by deoxycytidine kinase to be activated. Preliminary experiences. suggesting the activtty and the good tolerability of the drug on superficial transitional cell carcinoma of the bladder (TCCB) when administered by intravesical route, have been recently published. The mm of the present study was to evaluate the ablative efftcacy of weekly intravesical instillations of gemcitabine against paptllary marker lesions left after TUR of superficial TCCB. The scientific background and the ethical acceptability of thts approach have been balidated by the European Organization for Research and Treatment ot Cancer…

ANALOGHI DELLA SOMATOSTATINA:NUOVA TERAPIA DI SALVATAGGIO NEL CARCINOMA PROSTATICO ORMONO-RESISTENTE

GRAVE EMORRAGIA RICORRENTE DEL CONDOTTO ILEALE DA IPERTENSIONE PORTALE: PRIMA ESPERIENZA MONDIALE CON SCLEROTIZZAZIONE VASALE ECOGUIDATA.

-

GRAVE EMORRAGIA RICORRENTE DEL CONDOTTO ILEALE DA IPERTENSIONE PORTALE . PRIMA ESPERIENZA MONDIALE CON SCLEROTIZZAZIONE ECOGUIDATA

ASSOCIAZIONE DI SERENOA REPENS, URTICA DIOICA E PINUS PINASTER. SICUREZZA ED EFFICACIA NEL TRATTAMENTO DEI SINTOMI DEL BASSO TRATTO URINARIO. STUDIO PROSPETTICO SU 320 PAZIENTI

INTRODUCTION. Serenoa repens (saw palmetto) has been employed for the treatment of lower urinary tract symptoms (LUTS) for several years. Its mechanism of action is believed to be due to antiandrogenic, antiproliferative and antinflammatory properties. An association of Serenoa with the nettle “Utica dioica” showing antiproliferative activity and the pine “Pinus pinaster” derivative, showing antinflammatory action, has been proposed in recent years. Such an action is hoped to act not only by reducing LUTS but also by preventing the development of prostate cancer. MATHERIAL AND METHODS. During the years 2007 and 2008, 320 patients suffering from LUTS were treated with an association of Seren…

Uric acid, phosphate and oxalate stones: treatment and prophilaxis

VALUTAZIONE CLINICA DELLA PROTEINA 22 DELLA MATRICE NUCLEARE COME MARCATORE TUMORALE NEL FOLLOW-UP DEI TUMORI A CELLULE TRANSIZIONALI DELLA VESCICA

OBJECTIVES. Biomarkers (BTA, NMP22, FDP etc.) have been and continue to be evaluated as adjuncts or substitutes for cystoscopy, which is invasive and uncomfortable for some patients. Nuclear matrix protein-22 (NMP22) is involved in the regulation of nuclear processes. The main objective of the present study is to evaluate the clinical utility of urinary NMP22 as a tumor marker in the follow-up of transitional cell carcinoma (TCC) of the bladder. MATERIALS AND METHODS. The study included 62 patients undergoing follow-up, who had had TCC of bladder but who were disease-free at the beginning of the study, as confirmed by cystoscopy. Urine samples were collected for urinary cytology and NMP22 t…